News Archive

3 February 2014

Merck Animal Health Highlights the Importance of Effectively Managing Pancreas Disease at PD TriNation 2014

Attendees Gain Valuable Information on the Benefits of Vaccination Programs  

TRONDHEIM, NORWAY, 3 February, 2014 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) today announced the company is a major sponsor of the 2014 PD TriNation meeting, the international initiative on fish health to be held in Trondheim, Norway 4-5 February. The PD Trination initiative was established in 2005 with the aims to integrate and focus the activities of academia and industry from Norway, Ireland, Scotland and more recently other salmon farming regions.

“Pancreas disease (PD) can be devastating to fish farms because it can spread quickly through the farm, resulting in significant loss of fish and revenue,” explains Johan Kvalheim, Managing Director, Norway, Merck Animal Health. “We understand the importance of keeping fish healthy and are proud to partner again with PD TriNation to bring important data and educational information to the market.”

In addition to the sponsorship, the company will host three presentations to highlight the importance of PD control. The presentations are scheduled for 5 February and are:

  • 09:50 Cross-neutralization studies with SAV subtype 1-6 strains: results with sera from experimental studies and natural infections: Analysis of a combination of experimental antisera and sera from field outbreaks caused by known SAV subtype isolates. Results that will be presented showed the antibodies produced in salmon against SAV isolate of one subtype also recognize and neutralize isolates belonging to other subtypes.
  • 14:00 Contribution from vaccination and genetics in PD control: A summary of results from an experimental study where the contribution from vaccination with multivalent vaccines with or without PD-specific antigens will be presented. Results from the study and their implications for PD control will be discussed.
  • 14:20 PD Monitor and differential diagnosis techniques for Pancreas Disease: PD Monitor is a four stage support program for the salmon producers in Scotland and Ireland. Audits of the vaccination process, pre-transfer checks, mid-production and harvest assessments are conducted to assess the efficacy of the vaccine. Results from the PD Monitor program will be presented and the range of diagnostic techniques available to the industry discussed.

Attendees who are interested in joining the lecture, can visit trination.org or contact their Merck Animal Health sales representative.

About Merck Animal Health
Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.

Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).